• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型结核分枝杆菌 InhA 变构抑制剂在 C3HeB/FeJ 小鼠模型中的疗效及耐药潜能研究

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

机构信息

Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA

Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.

出版信息

Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02071-18. Print 2019 Apr.

DOI:10.1128/AAC.02071-18
PMID:30745397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6496157/
Abstract

AN12855 is a direct, cofactor-independent inhibitor of InhA in In the C3HeB/FeJ mouse model with caseous necrotic lung lesions, AN12855 proved efficacious with a significantly lower resistance frequency than isoniazid. AN12855 drug levels were better retained in necrotic lesions and caseum where the majority of hard to treat, extracellular bacilli reside. Owing to these combined attributes, AN12855 represents a promising alternative to the frontline antituberculosis agent isoniazid.

摘要

AN12855 是 InhA 的直接、辅因子非依赖性抑制剂。在 C3HeB/FeJ 鼠伴有干酪样坏死性肺病变的模型中,AN12855 显示出疗效,其耐药频率明显低于异烟肼。AN12855 药物水平在坏死病变和干酪样物中保留更好,而大部分难以治疗的细胞外细菌存在于其中。由于这些综合特性,AN12855 代表了一种有前途的替代一线抗结核药物异烟肼的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaee/6496157/2ac1d7f977cc/AAC.02071-18-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaee/6496157/2ac1d7f977cc/AAC.02071-18-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaee/6496157/2ac1d7f977cc/AAC.02071-18-f0003.jpg

相似文献

1
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.一种新型结核分枝杆菌 InhA 变构抑制剂在 C3HeB/FeJ 小鼠模型中的疗效及耐药潜能研究
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02071-18. Print 2019 Apr.
2
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.酪蛋白中性pH值最能解释吡嗪酰胺对C3HeB/FeJ小鼠结核病的选择性无活性。
Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43. doi: 10.1128/AAC.01370-15. Print 2016 Feb.
3
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.C3HeB/FeJ小鼠结核病模型中的异质性疾病进展和治疗反应
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
4
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.吡嗪酰胺与一线药物联合在C3HeB/FeJ小鼠结核病模型中的杀菌活性
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1091-6. doi: 10.1128/AAC.02637-15. Print 2016 Feb.
5
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.DprE1 抑制剂 BTZ-043 在 C3HeB/FeJ 小鼠结核模型中的药物分布和疗效。
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0059723. doi: 10.1128/aac.00597-23. Epub 2023 Oct 4.
6
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.在C3HeB/FeJ小鼠中,PA - 824在治疗潜伏性结核感染方面与异烟肼效果相当。
Int J Antimicrob Agents. 2014 Dec;44(6):564-6. doi: 10.1016/j.ijantimicag.2014.07.012. Epub 2014 Sep 16.
7
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.鼠结核性干酪样坏死肉芽肿模型可出现缺氧性病变。
J Infect Dis. 2012 Feb 15;205(4):595-602. doi: 10.1093/infdis/jir786. Epub 2011 Dec 23.
8
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.体外和体内氯法齐明抗结核分枝杆菌持续存活菌的活性。
Int J Tuberc Lung Dis. 2012 Aug;16(8):1119-25. doi: 10.5588/ijtld.11.0752. Epub 2012 Jun 12.
9
Fighting tuberculosis by drugs targeting nonreplicating bacilli.通过靶向非复制期杆菌的药物对抗结核病。
Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17.
10
Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.开发现代InhA抑制剂以对抗结核分枝杆菌的耐药菌株。
Curr Top Med Chem. 2007;7(5):489-98. doi: 10.2174/156802607780059781.

引用本文的文献

1
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.直接 InhA 抑制剂在结核分枝杆菌感染小鼠模型中新药物方案中的作用。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30.
2
How drug resistance has shaped anti-tubercular drug discovery.耐药性如何塑造抗结核药物的发现。
Front Cell Infect Microbiol. 2022 Sep 9;12:974101. doi: 10.3389/fcimb.2022.974101. eCollection 2022.
3
The Boron Advantage: The Evolution and Diversification of Boron's Applications in Medicinal Chemistry.

本文引用的文献

1
Discovery of a cofactor-independent inhibitor of InhA.InhA的一种不依赖辅因子的抑制剂的发现。
Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.
2
Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.休眠结核分枝杆菌在休眠的 Wayne 模型中将异烟肼转化为活性药物。
J Antibiot (Tokyo). 2018 Nov;71(11):939-949. doi: 10.1038/s41429-018-0098-z. Epub 2018 Sep 5.
3
Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.
硼的优势:硼在药物化学中的应用演变与多样化
Pharmaceuticals (Basel). 2022 Feb 22;15(3):264. doi: 10.3390/ph15030264.
4
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.DprE1 抑制剂 TBA-7371、PBTZ169 和 OPC-167832 在 C3HeB/FeJ 小鼠结核病模型中的药效学比较分析。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0058321. doi: 10.1128/AAC.00583-21. Epub 2021 Aug 9.
5
InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.InhA 抑制剂对非复制状态的结核分枝杆菌具有活性。
PLoS One. 2020 Nov 17;15(11):e0239354. doi: 10.1371/journal.pone.0239354. eCollection 2020.
6
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.新型结核病药物的研发:向敏感和耐多药结核病的方案组成的转化。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:495-516. doi: 10.1146/annurev-pharmtox-030920-011143. Epub 2020 Aug 17.
肺结核空洞小鼠模型及基质金属蛋白酶-9的表达
Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.
4
Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Infected C3HeB/FeJ Mice.贝达喹啉和吡嗪酰胺的治疗反应受感染的C3HeB/FeJ小鼠肺部病变异质性的影响。
ACS Infect Dis. 2016 Apr 8;2(4):251-267. doi: 10.1021/acsinfecdis.5b00127. Epub 2016 Feb 24.
5
The association between sterilizing activity and drug distribution into tuberculosis lesions.杀菌活性与药物在结核病灶中的分布之间的关联。
Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.
6
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.C3HeB/FeJ小鼠结核病模型中的异质性疾病进展和治疗反应
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
7
Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.用结核分枝杆菌气溶胶感染C3HeB/FeJ小鼠后,出现具有截然不同微环境的多种病变类型。
Dis Model Mech. 2015 Jun;8(6):591-602. doi: 10.1242/dmm.019570. Epub 2015 Mar 30.
8
Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review.结核分枝杆菌中与异烟肼耐药相关的基因突变:一项系统评价
PLoS One. 2015 Mar 23;10(3):e0119628. doi: 10.1371/journal.pone.0119628. eCollection 2015.
9
Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.小鼠潜伏性结核感染和再激活的新型坏死性肉芽肿模型的特征描述。
Am J Pathol. 2014 Jul;184(7):2045-55. doi: 10.1016/j.ajpath.2014.03.008. Epub 2014 May 9.
10
A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.一种双读出测定法,用于评估抗结核分枝杆菌化合物的效力。
PLoS One. 2013 Apr 4;8(4):e60531. doi: 10.1371/journal.pone.0060531. Print 2013.